Loading...
Prior studies have shown that treatment with ipilimumab plus nivolumab was more effective than ipilimumab alone for untreated patients with metastatic melanoma (N Engl J Med 2015; 373:23 and N Engl J Med 2015; 372:2006).
Now, investigators have conducted an industry-funded, multicenter, open-label, phase II study (CheckMate 204) to evaluate the efficacy and safety of this combination immunotherapy in 94 untreated metastatic melanoma patients with brain metastases. Patients received ipilimumab (2 mg/kg) plus nivolumab (1 mg/kg) every 3 weeks for up to 4 weeks followed by nivolumab (3 mg/kg) every 2 weeks.
At a median follow-up of 14 months, the rate of intracranial clinical benefit (the primary endpoint) was 57%; 26% of patients had a complete…